Effectiveness of Medium-Dose Ultraviolet A1 Phototherapy in Localized Scleroderma

Total Page:16

File Type:pdf, Size:1020Kb

Effectiveness of Medium-Dose Ultraviolet A1 Phototherapy in Localized Scleroderma Pharmacology and therapeutics Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma Ozlem Su1, MD, Nahide Onsun1, MD, Hulya Kapran Onay2, MD, Yeliz Erdemoglu1, MD, Dilek Biyik Ozkaya1, MD, Filiz Cebeci1, MD, and Adnan Somay3, MD 1Department of Dermatology, Abstract Bezmialem Vakif University, Faculty of Background Recently, ultraviolet (UV) A1 phototherapy has been suggested as an effec- 2 Medicine, Neoson Imaging Center, tive treatment for localized scleroderma (LS); however, the optimal dose of UVA1 still has Radiology, and 3Department of not been determined. Pathology, Vakif Gureba Teaching and 2 Research Hospital, Istanbul, Turkey Objective We aimed to evaluate the therapeutic effectiveness of medium-dose (30 J/cm ) UVA1 phototherapy and to show that 13 MHz ultrasound is a valuable tool for assessing Correspondence the results of UVA1 phototherapy in LS. Ozlem Su, MD Methods Thirty-five patients with LS were treated with medium-dose (30 J/cm2) UVA1. Sıgırtmac Sok. No. 21 B blok d. 7 In total, 30–45 treatments and 900–1350 J/cm2 cumulative UVA1 doses were evaluated by Osmaniye Bakirkoy clinical scoring in all patients. In 14 patients, skin thickness was also determined by Istanbul 13 MHz ultrasound examination. Turkey Results In all patients, medium-dose UVA1 therapy softened sclerotic plaques, and E-mail: [email protected] marked clinical improvement was observed in 29 of 35 (82. 85%) patients. Ultrasound mea- surements showed that skin thickness was significantly reduced. No side effects were Conflicts of interest: None. observed during or after treatment. Conclusion Medium-dose UVA1 phototherapy is a highly effective, safe, and well-tolerated therapeutic modality for treatment of all types of LS. A 13 MHz ultrasound probe may be used for evaluating UVA1 phototherapy results. developed lesions, the inflammatory cell infiltrate largely Introduction disappears, and dermal collagen bundles appear thick and Localized scleroderma, or morphea, is a connective tissue coarse and replace areas of subcutaneous fat.5 Rarely, disorder characterized by thickening and sclerosis of the morphea and lichen sclerosis et atrophicus (LSA) occur skin. A recent classification has grouped localized sclero- simultaneously in the same patient.6 derma into five subtypes: circumscribed morphea, linear Although the disease has a benign course, the lesions scleroderma (LS), generalized morphea, pansclerotic are cosmetically disfiguring and may cause psychological morphea, and a mixed subtype, when a combination of distress. Moreover, it sometimes progresses and may two or more of the previous subtypes is present.1 When involve underlying tissues of the skin (fat, fascia, and LS involves the face, it is called ‘‘en coup de sabre’’ muscle). This may lead to muscle atrophy, flexion con- (ECDS). A particularly rare subtype of localized sclero- tractures if localized over the joints, and poorly healing derma is bullous morphea.2 The most common circum- ulcerations that can cause significant morbidities.7,8 scribed morphea (plaque type) is characterized by single The pathogenesis of scleroderma has not been com- or multiple, circumscribed, ivory-white, indurated, some- pletely delineated, but three processes have been demon- times confluent plaques, which may be up to 20 cm in strated: disturbance of collagen metabolism,9 vascular diameter.3 During the active stages, lesions frequently alteration,10 and autoimmune activity.11 Fibrosis in sclero- expand with a violaceous border, the so-called lilac ring derma is preceded by a T-helper lymphocytic infiltrate (inflammatory halo).4 Histopathological examination of with subsequent collagen deposition and an increased syn- morphea during the active inflammatory stages in a thesis of type I and type III collagen. In fibroblasts from peripheral violaceous border shows a rather marked sclerotic skin lesions, increased collagen expression was inflammatory cell infiltrate, particularly in the reticular associated with decreased collagenase I expression, which 10 1006 dermis. In late sclerotic stages, as seen in the central well- may be important in collagen accumulation. International Journal of Dermatology 2011, 50, 1006–1013 ª 2011 The International Society of Dermatology Su et al. UVA1 phototherapy in localized scleroderma Pharmacology and therapeutics 1007 Numerous therapeutic agents have been used, with morphea, seven had late-stage sclerotic and 11 had active limited success, including topical, intralesional, and inflammatory lesions. One patient with linear morphea had systemic glucocorticoids, penicillin G, D-penicillamine, upper limb involvement associated contractures. Four patients antimalarials, sulfasalazine, vitamin D analogs, vitamin E, with generalized morphea presented with late-stage lesions. imiquimod, topical tacrolimus, etretinate, potassium The remaining three patients with generalized morphea p-aminobenzate, griseofulvin, interferon gamma, metho- presented with active inflammatory lesions. The disease trexate, cyclosporine, phototherapy, and extracorporeal duration varied between three months and 55 years. Before photopheresis.4,7,12,13 treatment, skin biopsies were taken from lesional skin. Recently, different types of phototherapy, such as psor- Unfortunately, post-treatment histopathological examination was alen and ultraviolet (UV) A,14 broadband UVA (320– done on only four of these patients. Fourteen of 35 patients 400 nm),15 and UVA1 (340–400 nm)4,10,11 have been were evaluated by clinical score as well as by 13 MHz advocated as a new line of therapy, based on the finding ultrasound. that synthesis of collagenase can be directly stimulated in human skin fibroblasts by UVA radiation. Very promising Ultraviolet A1 equipment results have notably been achieved with UVA1 photother- The UVA1 irradiation equipment consisted of a Waldmann apy thus far, with low-dose (LD) and medium-dose (MD) 7001 K cabin with Waldmann TL10R low-pressure lamps UVA1 seeming to be as effective as high-dose (HD) (Waldmann Gmblt, Schvenningen, Germany). These lamps UVA1, with a possible better risk–benefit ratio.4,10,11,16 generate UVA1 wavelengths in the 340–400 nm range. In The optimal dose regarding therapeutic efficacy vs. possi- addition, infrared irradiation is emitted, but this is filtered out by ble side effects remains to be evaluated. an acrylic glass screen. The UVA1 irradiation levels are We aimed to evaluate the therapeutic effectiveness of approximately 35 mW/cm2. A dose of 30 J/cm2 is achieved in MD (30 J/cm2) UVA1 phototherapy and to show that approximately 30 minutes. 13 MHz ultrasound is a valuable tool for the assessment of diagnosis and treatment results in LS. Treatment In all patients, total body UVA1 phototherapy (340–400 nm) was administered 3–5 times a week for 10–15 weeks, resulting Materials and methods in a total of 30–45 treatment sessions. Each treatment session Patients consisted of an exposure of 30 J/cm2 UVA1 per body half, Thirty-five patients with localized scleroderma were selected for resulting in a cumulative UVA1 dose of 900–1350 J/cm2. During MD UVA1 phototherapy and were treated after informed therapy, patients wore eye goggle protection against UVA consent at our dermatology clinic between April 2005 and June radiation. Emollients had been applied once daily in the 2009. For each patient, a complete disease history was evening. Emollients were not applied shortly before or after obtained before starting irradiation therapy. Laboratory UVA1 phototherapy. examinations included complete blood cell count, liver and kidney parameters, rheumatoid factor, antinuclear antibodies, Assessment and serology for Borrelia burgdorferi. In all patients (27 female and 8 male; age 3.5–75 years), the diagnosis of LS was made Clinical evaluation on clinical and histopathological features. None of the patients All patients were assessed before, during, and after UVA1 had any evidence of systemic sclerosis or pseudoscleroderma. phototherapy by palpation for tethering and thickening of the All patients had at least two clinically identical scleroderma skin. Clinical severity of LS was assessed by a scoring system lesions (mostly contralateral). All patients included in the study created by Rook et al.17 Briefly, the method consists of scoring were Caucasian; 15 patients had skin type II, 15 had skin type sclerosis of different topographic sites. The most severely III, and five had skin type IV according to Fitzpatrick’s affected site selected for assessment of clinical severity was classification. Exclusion criteria were as follows: pregnancy or examined in each patient by the same investigator (OS). The lactation, any internal immunomodulation or immunosuppressive severity of sclerosis was scored from 0 (like normal skin) to 10 therapy within the last four weeks, any topical therapy within the (extremely sclerotic, wooden hard). last two weeks other than the use of emollients, current use of potentially photosensitizing drugs, history of relevant cardiac/ Ultrasound analysis (13 MHz) cardiovascular events, and a history of an autoimmune disease Ultrasound imaging was performed with a high-resolution or neoplasm. Patients were classified to have plaque (n = 18), B-mode ultrasound system (Sanoline Antares; Siemens Medical linear (n = 4), ECDS (n = 3), generalized morphea (n = 7), deep System, Erlangen, Germany) with a 13 MHz CVFX 13-5 linear or pansclerotic (n = 1), and generalized associated with probe by a second investigator (HK). The usable depth of signal overlying LSA (n = 2) subtypes.
Recommended publications
  • Autoimmune Associations of Alopecia Areata in Pediatric Population - a Study in Tertiary Care Centre
    IP Indian Journal of Clinical and Experimental Dermatology 2020;6(1):41–44 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Autoimmune associations of alopecia areata in pediatric population - A study in tertiary care centre Sagar Nawani1, Teki Satyasri1,*, G. Narasimharao Netha1, G Rammohan1, Bhumesh Kumar1 1Dept. of Dermatology, Venereology & Leprosy, Gandhi Medical College, Secunderabad, Telangana, India ARTICLEINFO ABSTRACT Article history: Alopecia areata (AA) is second most common disease leading to non scarring alopecia . It occurs in Received 21-01-2020 many patterns and can occur on any hair bearing site of the body. Many factors like family history, Accepted 24-02-2020 autoimmune conditions and environment play a major role in its etio-pathogenesis. Histopathology shows Available online 29-04-2020 bulbar lymphocytes surrounding either terminal hair or vellus hair resembling ”swarm of bees” appearance depending on chronicity of alopecia areata. Alopecia areata in children is frequently seen. Pediatric AA has been associated with atopy, thyroid abnormalities and a positive family history. We have done a study to Keywords: find out if there is any association between alopecia areata and other auto immune diseases in children. This Alopecia areata study is an observational study conducted in 100 children with AA to determine any associated autoimmune Auto immunity conditions in them. SALT score helps to assess severity of alopecia areata. Severity of alopecia areata was Pediatric population assessed by SALT score-1. S1- less than 25% of hairloss, 2. S2- 25-49% of hairloss, 3. 3.S3- 50-74% of hairloss.
    [Show full text]
  • The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S
    ORIGINAL ARTICLE The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S. Antunes1, Amelia R. Aguilera1, Koji Tamada2 and Michael Croft1 Several inflammatory diseases including scleroderma and atopic dermatitis display dermal thickening, epidermal hypertrophy, or excessive accumulation of collagen. Factors that might promote these features are of interest for clinical therapy. We previously reported that LIGHT, a TNF superfamily molecule, mediated collagen deposition in the lungs in response to allergen. We therefore tested whether LIGHT might similarly promote collagen accumulation and features of skin fibrosis. Strikingly, injection of recombinant soluble LIGHT into naive mice, either subcutaneously or systemically, promoted collagen deposition in the skin and dermal and epidermal thickening. This replicated the activity of bleomycin, an antibiotic that has been previously used in models of scleroderma in mice. Moreover skin fibrosis induced by bleomycin was dependent on endogenous LIGHT activity. The action of LIGHT in vivo was mediated via both of its receptors, HVEM and LTβR, and was dependent on the innate cytokine TSLP and TGF-β. Furthermore, we found that HVEM and LTβR were expressed on human epidermal keratinocytes and that LIGHT could directly promote TSLP expression in these cells. We reveal an unappreciated activity of LIGHT on keratinocytes and suggest that LIGHT may be an important mediator of skin inflammation and fibrosis in diseases such as scleroderma
    [Show full text]
  • Decreased Adhesion Molecules Expression on Granuloma Forming
    THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 22 (1), 2015 Page: 29-40 Level of IL-16 and Reticulated Platelets Percentage during the Clinical Course of Immune Thrombocytopenic Purpura in Children 1Reem R. Abd El-Glil, 2Effat H. Assar Departments of 1Microbiology & Immunology and 2Pediatric, Faculty of Medicine, Benha University, Benha, Egypt. Immune thrombocytopenic purpura (ITP) is an immune-mediated acquired disease with transient or persistent decrease of thrombocytes number in the blood. Cytokines play important roles in the immune regulation and are known to be deregulated in autoimmune diseases. This study aimed to investigate serum IL-16 levels in relation to reticulated platelets in children with ITP and platelet count. Twenty six children with ITP (11 with newly diagnosed ITP, 9 with persistent ITP and 6 with chronic ITP) and 12 age-matched healthy children controls were studied. Serum level of IL-16 and reticulated platelets count were assessed by Enzyme Linked Immunosorbent Assay (ELISA) and flow cytometry respectively. Serum IL-16 levels were significantly higher in patients as compared to controls (P<0.001).Within patients, the levels were higher in newly diagnosed compared to persistent and chronic ITP (P<0.01) and (P<0.001) respectively. IL-16 levels were also significantly higher in persistent ITP compared to chronic ITP (P<0.001). Reticulated platelets were also elevated in patients compared to controls and the increase was significant in newly diagnosed group (P<0.05). Negative correlation was found between IL-16 level and reticulated platelets and platelets counts (r=-0.284, P=0.028, r=0.274 P=0.25) respectively.
    [Show full text]
  • Dupilumab Is a Predominant Treatment for Recalcitrant Bullous Pemphigoid
    Somato Publications ISSN: 2688-1071 Archives of Clinical Case Reports Case Report Dupilumab is a Predominant Treatment for Recalcitrant Bullous Pemphigoid Nozomi Yonei* Division of Dermatology, Naga Municipal Hospital, 1282 Uchita, Kinokawa, Wakayama 649-6414, Japan *Address for Correspondence: Nozomi Yonei, Division of Dermatology, Naga Municipal Hospital, 1282 Uchita, Kinokawa, Wakayama 649-6414, Japan, Tel: +81-736-77-2019; E-mail: [email protected] Received: 01 February 2021; Accepted: 22 February 2021; Published: 24 February 2021 Citation of this article: Nozomi Yonei. (2020) Dupilumab is a Predominant Treatment for Recalcitrant Bullous Pemphigoid. Arch Clin Case Rep, 4(1): 01-04. Copyright: © 2021 Nozomi Yonei. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Bullous pemphigoid is occasionally recalcitrant to established medications. Our 72-year-old male patient was treated with established medications such as systemic corticosteroid (prednisone 1.3_0.7mg/kg), methylprednisolone pulse therapy, 7 up, and many complications such as aspiratory pneumonia, chronic urinary infection, hypoalbuminemia were observed. doses of monthly intravenous immunoglobulin, cyclosporine. During tapering of prednisone, the disease activity easily flared Given the patient’s severe disease status and treatment limitations, we introduced dupilumab expecting Th2-suppressive effect, according to the dosing regimen approved for atopic dermatitis. After 2 months of dupilumab therapy, BPDAI (Bullous Pemphigoid Disease Area Index) score halved, and after 3 months, he accomplished the clearance of the lesions. A place- bo-controlled phase 3 clinical trial of dupilumab for severe BP is now under way, and it is expected that the effectiveness of dupilumab for BP will be proved in the near future.
    [Show full text]
  • Understanding Eczema / Atopic Dermatitis
    Understanding Atopic Dermatitis An educational health series from National Jewish Health If you would like further information about National Jewish Health, please write to: National Jewish Health 1400 Jackson Street Denver, Colorado 80206 or visit: njhealth.org Understanding Atopic Dermatitis An educational health series from National Jewish Health IN THIS ISSUE About Atopic Dermatitis 2 What Causes Atopic Dermatitis? 3 Do You Have Atopic Dermatitis? 3 Should You Go to an Expert? 4 What Are Your Goals? 4 Avoiding Things that Make Itching and Rash Worse 5 Treatment and Medication Therapy 9 Soak and Seal 9 What Medicines Will Help? 10 Action Plan for Atopic Dermatitis 13 What to Do When Symptoms Are Severe 14 Living with Atopic Dermatitis 15 Remember Your Goals 15 Glossary 16 Note: This information is provided to you as an educational service of National Jewish Health. It is not meant as a substitute for your own doctor. © Copyright 2018, National Jewish Health About Atopic Dermatitis Atopic dermatitis is a common chronic skin disease. It is also called atopic eczema. Atopic is a term used to describe allergic conditions such as asthma and hay fever. Both dermatitis and eczema mean inflammation of the skin. People with atopic dermatitis tend to have dry, itchy and easily irritated skin. They may have times when their skin is clear and other times when they have rash. INFANTS AND SMALL CHILDREN In infants and small children, the rash is often present on face, as well as skin around the knees and elbows. TEENAGERS AND ADULTS In teenagers and adults, the rash is often present in the creases of the wrists, elbows, knees or ankles, and on the face or neck.
    [Show full text]
  • Association of Atopic Dermatitis with Rheumatoid Arthritis and Systemic Lupus Erythematosus in US Adults
    Association of atopic dermatitis with rheumatoid arthritis and systemic lupus erythematosus in US adults Alexander Hou, BS1, Jonathan I. Silverberg, MD, PhD, MPH2 1Department of Dermatology, Feinberg School of Medicine, Northwestern University. 2Department of Dermatology, George Washington University School of Medicine, Washington D.C., USA https://orcid.org/0000-0003-3686-7805 Twitter: @JonathanMD Background: There have been conflicting studies about the association of atopic dermatitis (AD) and autoimmune disorders, e.g. rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Little is known about which subsets of AD patients have increased likelihood to develop autoimmune disorders. Objective: We sought to determine whether AD with or without atopic comorbidities is associated with RA and SLE, and which subsets of adults have increased likelihood of RA and SLE. Methods: Data were analyzed from the 2012 National Health Interview Survey, a representative United States population-based cross-sectional survey study (n=34,242 adults age ≥18 years). Results: In bivariate and multivariate weighted logistic regression models, RA was associated with AD overall (adjusted odds ratio [95% confidence interval]: 1.65 [1.27-2.16]), and AD with comorbid asthma (2.27 [1.46-3.52]), hay fever (1.76 [1.03-3.02]), food allergy (2.05 [1.23- 3.42]), or respiratory allergy (1.75 [1.14-2.68]). RA was associated with AD without atopic comorbidities in bivariate models, but not in multivariate models adjusting for sociodemographic characteristics (1.44 [0.95-2.19]). Similarly, SLE was associated with AD overall (2.62 [1.40- 4.90]), and AD with comorbid asthma (2.75 [1.13-6.70]), food allergy (6.58 [2.71-16.0]), or respiratory allergy (5.34 [2.21-12.9]), but not AD alone (1.44 [0.59-3.50]) or AD with comorbid hay fever (1.37 [0.33-5.75]).
    [Show full text]
  • Canine Atopic Dermatitis- Part 1 Michele R
    What’s New in Canine Atopic Dermatitis- Part 1 Michele R. Rosenbaum VMD, DACVD Canine atopic dermatitis (AD) is a common genetically-based inflammatory and pruritic allergic skin disease with characteristic clinical features associated with IgE; it is most commonly directed against environmental allergens. According to various investigators, the incidence has been reported to be approximately 10% of the worldwide canine population that visits veterinarians.1 Atopy is defined as the inherited predisposition to form allergen-specific IgE antibodies but does not always mean clinical disease (atopic dermatitis) will develop, as normal dogs can have allergen-specific IgE in their skin or serum. Note the nomenclature change from allergic inhalant dermatitis to atopic dermatitis (AD) (similar to human atopic eczema) due to recent research which has demonstrated that transcutaneous allergen penetration through a defective skin barrier rather than inhalation is the primary method of allergen absorption.2 Inhalation and oral ingestion of allergens are minor routes of exposure. AD is a clinical diagnosis made by ruling out all other causes of itching, not one made by allergy testing. It is a syndrome triggered by environmental allergens, food allergens, and microbial colonization with Staphylococcus and Malassezia. In the classic form of AD, it is associated with IgE antibodies to these allergens. Atopic-like Dermatitis (ALD) is a newly described variant of atopic dermatitis similar to intrinsic AD in humans in which affected dogs show all of the clinical signs of AD without skin or serum testing evidence of IgE- mediated hypersensitivity to environmental or other allergens.3 In people, the disease is thought to have a genetic predisposition.
    [Show full text]
  • Atopic Dermatitis in Children, Part 1: Epidemiology, Clinical Features, and Complications
    PEDIATRIC DERMATOLOGY Series Editor: Camila K. Janniger, MD Atopic Dermatitis in Children, Part 1: Epidemiology, Clinical Features, and Complications David A. Kiken, MD; Nanette B. Silverberg, MD Atopic dermatitis (AD), also known as eczema, incidence is not believed to vary by ethnicity. Chil- is a chronic skin condition, characterized by dren in smaller families of a higher socioeconomic itch (pruritus) and dryness (xerosis). AD lesions class in urban locations are more likely to be affected appear as pruritic red plaques that ooze when than children of other backgrounds. scratched. Children with AD are excessively sensi- Certain types of AD are more clinically prevalent tive to irritants such as scented products and dust among certain ethnic groups.3 Facial and eyelid der- due to their impaired skin barrier and skin immune matitis are more common in Asian infants and teen- responses. AD is among the most common disor- aged girls. Follicular eczema, a variant characterized ders of childhood and its incidence is increasing. by extreme follicular prominence, is most common AD is an all-encompassing disease that causes in black individuals. One subtype of AD, a num- sleep disturbances in the affected child, disrupt- mular variety, named for the coinlike appearance ing the entire household. Patients with AD also of lesions, often is associated with contact allergens are prone to bacterial overgrowth, impetigo, and (ie, allergy to substances that come in contact with extensive viral infections. Consequently, familiarity the skin), including thimerosal, a preservative used with the most recent literature is of utmost impor- in pediatric vaccines.3 tance so that dermatologists and pediatricians can appropriately manage their patients.
    [Show full text]
  • Eczema Vs Urticaria – Not All Rashes Are Equal
    REVIEW Eczema vs urticaria – not all rashes are equal S Davis Amayeza Information Services Corresponding author, email: [email protected] Abstract Although clinically distinctive, urticaria may be confused with other dermatological diseases including eczema. Eczema (also called atopic dermatitis) is a chronic pruritic inflammatory skin disorder that occurs most frequently in children but can also affect adults. Symptoms occur due to skin barrier abnormalities and the main objective of treatment is to improve inflammation and xerosis with emollients and, in some patients, low potency topical corticosteroids. In contrast, urticaria occurs in all age groups and presents as transient, distinct, round or oval lesions and severe pruritis. The goal of treatment is to relieve itching with antihistamines and to manage angioedema (if present). Identification and avoidance of triggers is recommended, where possible, to prevent future recurrences of urticaria. Keywords: eczema, urticaria, dermatological diseases, chronic pruritic inflammatory skin disorder © Medpharm S Afr Pharm J 2020;87(2):22-25 Introduction Urticaria Eczema affects approximately 5–20% of children worldwide.1 In In contrast to eczema, urticarial lesions are self-limiting and the vast majority of cases, eczema has an onset before age five of short duration, usually resolving within 24 hours without years and up to 40% of cases may continue into adulthood.2 scarring.7,8 Lesions can occur on any part of the body but areas Eczema is common in patients with a family history of asthma, where clothing compresses the skin (e.g. under waistbands) may eczema or allergic rhinitis.1 be affected more dramatically. Compressed areas may become more severely affected once the restrictive clothing is removed.
    [Show full text]
  • A Case of Atopic Dermatitis Co-Existing with Psoriasis Vulgaris
    erimenta xp l D E e r & m l a a t c o i l n o i Journal of Clinical & Experimental l g y C Sugiura and Sugiura, J Clin Exp Dermatol Res f R o e l ISSN: 2155-9554 s a e n 2017, 8:2 a r r u c o h J Dermatology Research DOI: 10.4172/2155-9554.1000386 Case Report Open Access A Case of Atopic Dermatitis Co-existing with Psoriasis Vulgaris Keiji Sugiura* and Mariko Sugiura Department of Environmental Dermatology & Allergology, Daiichi Clinic, Japan *Corresponding author: Keiji Sugiura, Department of Environmental Dermatology & Allergology, Daiichi Clinic, Nittochi Nagoya Building, 2F, 1-1 Sakae 2, Nakaku, Nagoya, 468-0008, Japan, Tel: +81-52-204-0834; Fax: +81-52-204-0834; E-mail: [email protected] Received date: February 24, 2017; Accepted date: March 06, 2017; Published date: March 08, 2017 Copyright: © 2017 Sugiura K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract The coexistence of atopic dermatitis (AD) and psoriasis has been not impossible, because their respective immunological situations involve distinct reactions. Recently, there are some reports of comorbidity of AD and psoriasis. Here we present the case of a patient with AD who developed psoriasis. A 43-year-old female developed AD, and new erythema has increased over 40 years. The results of skin biopsy showed psoriasis-form changes. We started to treat her using cyclosporine, second-generation anti-histamine tablets, steroid ointments, and Dovobet® ointment under a diagnosis of AD with psoriasis.
    [Show full text]
  • Understanding Atopic Dermatitis Know Your Skin – from the Inside Out
    Understanding Atopic Dermatitis Know Your Skin – From the Inside Out Special Edition of ATOPIC DERMATITIS DEFINED Who We Are Allergy & Asthma Network is the leading nonprofit patient outreach, education, advocacy and research organization for people with asthma, allergies and related conditions. 8229 Boone Blvd. Suite 260 Our patient-centered network Vienna, VA 22182 unites individuals, families, 800.878.4403 healthcare professionals, industry AllergyAsthmaNetwork.org leaders and government decision- [email protected] makers to improve health and quality of life for the millions of Understanding Atopic Dermatitis people affected by asthma and – Allergy & Asthma Today Special allergies. Edition is published by Allergy & Asthma Network, Copyright An innovator in encouraging 2018. All rights reserved. family participation in treatment plans, Allergy & Asthma Network Call 800.878.4403 to order specializes in making accurate copies; shipping and handling medical information relevant charges apply. and understandable to all while promoting standards of care that are proven to work. We believe PUBLISHER that integrating prevention with Allergy & Asthma Network treatment helps reduce emergency healthcare visits, keep children in PRESIDENT AND CEO school and adults at work, and Tonya Winders allow participation in sports and other activities of daily life. MANAGING EDITOR Gary Fitzgerald Our Mission CREATIVE DIRECTOR To end needless death and suffering Paul Tury due to asthma, allergies and related conditions through outreach, DIRECTOR OF EDUCATION education, advocacy and research. Sally Schoessler CONTRIBUTORS Allergy & Asthma Network is a Allie Bahn 501(c)(3) organization. Tracy Bush Kortney Kwong Hing Join Allergy & Asthma Network Abby Lai today, as we work to help Kimberly Pellicore patients and families Laurie Ross breathe better together.
    [Show full text]
  • A New Treatment for Seborrheic Dermatitis
    Pimecrolimus: A New Treatment for Seborrheic Dermatitis Charles E. Crutchfield III, MMB, MD Seborrheic dermatitis is a chronic recurrent involved in the inflammatory response. Specifically, inflammatory skin condition that mainly affects pimecrolimus inhibits calcineurin, a calcium- areas containing sebaceous glands. I present a dependent phosphatase enzyme. As a result, macrolac- case of a novel effective topical nonsteroidal tam immunomodulators also are known as calcineurin treatment (pimecrolimus 1.0% cream) for facial inhibitors. Calcineurin is essential in activating a seborrheic dermatitis. Pimecrolimus is a member nuclear transcription factor of activated T cells—a of a new class of nonsteroidal agents— factor that enhances production of many of the macrolactam immunomodulators. cytokines involved in the inflammatory response. Pimecrolimus seems to not produce the side effects eborrheic dermatitis is a chronic recurrent common with chronic use of topical steroids.7,8 inflammatory skin condition that affects the S nasolabial folds, ears, eyebrows, scalp (dan- Case Report druff), chest, umbilicus, and other areas containing A 33-year-old man presented with pink-to-red sebaceous glands.1 This condition also may have patches and plaques on the central area of the face hormonal influences—hence the appearance of (including the nasolabial folds) and overlying greasy seborrheic dermatitis on both the scalp in infants scales (Figure 1A). Ear, scalp, and chest involve- younger than 6 months (cradle cap) and on sebum- ment was minimal. The rash, which had been 1-3 1 rich areas in postadolescents. Seborrheic dermati- present intermittently for 1 /2 years, was progressing tis also has been associated with Pityrosporum in severity and frequency and was failing to respond yeasts, AIDS, and neurologic disease.4-6 The course to over-the-counter hydrocortisone 1% cream.
    [Show full text]